romidepsin
Showing 1 - 25 of 58
Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma Trial run by the NCI (Romidepsin,
Recruiting
- Cutaneous T-Cell Lymphoma
- +3 more
- Romidepsin
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell
Active, not recruiting
- Recurrent Anaplastic Large Cell Lymphoma
- +10 more
- Pembrolizumab
- Romidepsin
-
Houston, TexasM D Anderson Cancer Center
Jan 30, 2023
Multiple Myeloma, Non-Hodgkin's Lymphoma Trial in United States (Romidepsin, Lenalidomide)
Active, not recruiting
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
- Romidepsin
- Lenalidomide
-
Hartford, Connecticut
- +6 more
Jan 3, 2023
Lymphoma, T-Cell Trial in Charlottesville (Durvalumab, Pralatrexate, Romidepsin)
Recruiting
- Lymphoma, T-Cell
- Durvalumab
- +3 more
-
Charlottesville, VirginiaUniversity of Virginia
Mar 16, 2022
Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma Trial run by
Not yet recruiting
- Adult T-cell Leukemia/Lymphoma
- +4 more
- CC-486 (5-azacitidine)
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
Lymphoma, Relapsed/Refractory T-cell Lymphomas Trial in United States (Romidepsin, Bortezomib, duvelisib)
Active, not recruiting
- Lymphoma
- Relapsed/Refractory T-cell Lymphomas
- Romidepsin
- +2 more
-
Stanford, California
- +10 more
Feb 2, 2023
Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell
Active, not recruiting
- Anaplastic Large Cell Lymphoma
- +2 more
- Laboratory Biomarker Analysis
- +2 more
-
Duarte, California
- +1 more
Jul 26, 2022
Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia, T-Large Granulocytic Leukemia Trial in Columbus (Romidepsin, Busulfan,
Recruiting
- Cutaneous T-cell Lymphoma
- +4 more
- Romidepsin
- +4 more
-
Columbus, OhioThe Ohio State University Cancer Center
Apr 18, 2022
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous
Recruiting
- Recurrent Anaplastic Large Cell Lymphoma
- +8 more
- Parsaclisib
- Romidepsin
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Apr 6, 2022
HIV Trial in United States (Romidepsin, Placebo for Romidepsin)
Completed
- HIV Infections
- Romidepsin
- Placebo for Romidepsin
-
Birmingham, Alabama
- +9 more
Oct 28, 2021
Triple-Negative Breast Cancer, Breast Cancer Trial in United States (Romidepsin, Cisplatin, Nivolumab)
Active, not recruiting
- Triple-Negative Breast Cancer
- Breast Cancer
- Romidepsin
- +2 more
-
Fairway, Kansas
- +6 more
Nov 19, 2021
Colorectal Cancer Trial in Baltimore (Oral CC-486, Romidepsin, MK-3475)
Completed
- Colorectal Cancer
- Oral CC-486
- +2 more
-
Baltimore, MarylandJohns Hopkins Sidney Kimmel Comprehensive Cancer Center
Mar 21, 2022
Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma Trial in Germany (Romidepsin, Azacitidine,
Recruiting
- Pancreas Cancer
- +2 more
- Romidepsin
- +5 more
-
Essen, Germany
- +8 more
May 17, 2022
Hiv Trial in Denmark, United Kingdom (Romidepsin, 3BNC117, Antiretrovirals)
Active, not recruiting
- Hiv
- Romidepsin
- +2 more
-
Aalborg, Denmark
- +6 more
Sep 3, 2021
Human Immunodeficiency Virus (HIV) Trial in New York, Aarhus, Cologne (3BNC117, Romidepsin)
Completed
- Human Immunodeficiency Virus (HIV)
- 3BNC117
- Romidepsin
-
New York, New York
- +2 more
Feb 3, 2021
Lymphoid Malignancies, Lymphoma, Hodgkin Lymphoma Trial in New York (Romidepsin, Oral 5-Azacitidine)
Terminated
- Lymphoid Malignancies
- +3 more
- Romidepsin
- Oral 5-Azacitidine
-
New York, New YorkColumbia University Medical Center
Jan 5, 2021
Lymphoma, T-Cell, Peripheral Trial in United States (Romidepsin, Ixazomib)
Active, not recruiting
- Lymphoma, T-Cell, Peripheral
- Romidepsin
- Ixazomib
-
Chicago, Illinois
- +6 more
Jan 15, 2021
Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Disease Trial in Chicago, Saint Louis (Romidepsin,
Completed
- Lymphoma, T-Cell, Cutaneous
- +3 more
- Romidepsin
- +4 more
-
Chicago, Illinois
- +1 more
Nov 16, 2020
Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma Trial in Worldwide (Oral azacitidine,
Active, not recruiting
- Relapsed Angioimmunoblastic T-Cell Lymphoma
- Refractory Angioimmunoblastic T-cell Lymphoma
- Oral azacitidine
- +3 more
-
Graz, Austria
- +33 more
Aug 24, 2022
Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell
Completed
- Stage IV Squamous Cell Carcinoma of the Hypopharynx
- +3 more
- romidepsin
-
Boston, Massachusetts
- +1 more
Feb 11, 2021
Lymphoid Malignancies, Multiple Myeloma, Lymphoma Trial in Boston, New York (Pralatrexate, Romidepsin)
Unknown status
- Lymphoid Malignancies
- +4 more
- Pralatrexate
- Romidepsin
-
Boston, Massachusetts
- +1 more
Feb 6, 2020
Hematologic Malignancy, Malignant Lymphoma Trial in Sarasota, Nashville, London (Romidepsin, Rifampin)
Completed
- Hematologic Malignancy
- Malignant Lymphoma
- Romidepsin
- Rifampin
-
Sarasota, Florida
- +2 more
Nov 14, 2019